FDA approves Revolution Medicines' RASONQUE for metastatic pancreatic adenocarcinoma

Revolution Medicines, Inc.

• FDA approved RASONQUE (daraxonrasib) on Aug 26, 2026 for adult patients with metastatic pancreatic adenocarcinoma after prior systemic therapy or ineligible for multiagent therapy.
• Approval based on RASolute 302, a global randomized Phase 3 trial vs investigator's choice of cytotoxic chemotherapy in previously treated patients.
• Once-daily oral RASONQUE tablets now available in the U.S. for eligible patients; wholesale acquisition cost $39,800 for 30-day supply.
• This is the first FDA approval for Revolution Medicines' RAS inhibitor, marking a major commercial milestone.